Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific senior vice president and chief HR officer Lisa P. Britt reported equity awards that increase her direct ownership in the company. She received a grant of stock options for 5,139 shares at an exercise price of $0.00 per option, along with grants of 872 and 1,173 shares of common stock.
The common stock relates to a performance-based restricted stock unit award originally granted on February 19, 2025, for which the compensation committee determined on February 25, 2026, that the performance criteria were satisfied. One-third of these shares vest on February 28, 2026 and 2027, with the remaining third vesting on February 28, 2028 subject to adjustment based on total shareholder return CAGR versus a peer group over the period from January 1, 2025 through December 31, 2027. The option award vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific Executive Vice President Frederick M. Lowery reported an equity award and updated share holdings. He acquired 1,638 shares of common stock through a performance-based restricted stock unit award originally granted on February 19, 2025, after the Compensation Committee certified performance on February 25, 2026. The award is scheduled to vest in three equal tranches on February 28, 2026, 2027, and 2028. A separate performance-based award granted on February 22, 2023 was reduced by 15% based on relative total shareholder return, resulting in 64 fewer shares than previously reported. Between December 2, 2025 and February 26, 2026, he also acquired 10.854 shares of TMO common stock in the company’s 401(k) plan and reports additional indirect holdings through a limited liability company, while disclaiming beneficial ownership of indirectly held shares except for any pecuniary interest.
Thermo Fisher Scientific senior vice president and general counsel Thomas B. Shropshire Jr. reported equity awards on common stock and stock options. He received a grant of stock options for 4,281 shares at an exercise price of $0.0000 and a separate award of 978 shares of common stock, both recorded as direct ownership.
The filing notes that the option grant vests in four equal annual installments beginning on February 28, 2027, meaning the right to exercise the full option stretches over four years from that date.
Shafer Michael D reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported equity awards and adjustments to his holdings. He received a grant of 13,698 stock options and two performance-based stock unit-related common stock awards totaling 4,698 shares.
The filing explains that a performance-based restricted stock unit award granted on February 19, 2025 met its performance criteria on February 25, 2026, with one-third of the shares vesting on February 28, 2026 and 2027, and the final third vesting on February 28, 2028 subject to potential positive or negative adjustment. It also records a 15% reduction to the final tranche of an earlier 2023 performance-based award, resulting in 56 fewer shares than previously reported. The new stock option vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific VP & Chief Accounting Officer Joseph R. Holmes reported equity awards tied to performance-based stock programs. He acquired 985 stock options at an exercise price of $0.0000 per option and 433 shares of common stock as a performance-based restricted stock unit award.
An additional 337 shares of common stock were reported as an adjustment to the final tranche of a 2023 performance-based restricted stock unit award after a 15% reduction in the payout, which resulted in 6 fewer shares than previously reported. The new option grant vests in four equal annual installments beginning on February 28, 2027, and the 2025 performance-based award vests in thirds on February 28, 2026, 2027, and 2028, with the last third still subject to long-term total shareholder return performance.
Pettiti Gianluca reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific executive vice president Gianluca Pettiti reported equity awards that increase his direct holdings in company stock. He received a grant of stock options for 16,270 shares and performance-based restricted stock units that resulted in 2,057 and 3,715 shares of common stock being credited to him.
The performance-based award was granted on February 19, 2025, and the company’s compensation committee determined on February 25, 2026 that its performance criteria were satisfied. One-third of these shares vest on February 28, 2026 and 2027, while the remaining one-third vests on February 28, 2028 and may be adjusted up or down based on relative total shareholder return performance. The stock option grant vests in four equal annual installments beginning on February 28, 2027.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper reported equity awards tied to performance and long-term incentives. He acquired 32,109 stock options at an exercise price of $0.00 per share, which vest in four equal annual installments beginning on February 28, 2027.
He also acquired 7,515 and 7,333 shares of common stock through performance-based restricted stock unit awards granted in February 2025, after the compensation committee determined on February 25, 2026 that performance criteria were satisfied. One-third of these shares vest on February 28, 2026 and February 28, 2027, with the remaining one-third vesting on February 28, 2028 subject to adjustment based on relative total shareholder return CAGR.
The filing also lists indirect holdings in Thermo Fisher shares by the Alison Casper 2020 Irrevocable Trust, Floral Park Associates, Inc., and the MNC 2020 Irrevocable Trust, for which Casper disclaims beneficial ownership except for any pecuniary interest.
Thermo Fisher Scientific reported full-year 2025 revenue of $44.56 billion, up 4%, with GAAP diluted EPS of $17.74 and adjusted EPS of $22.87. GAAP operating income rose to $7.75 billion, and adjusted operating income reached $10.11 billion, with margins improving slightly.
Organic revenue grew 2%, helped by pharma and biotech demand and industrial and applied markets, while academic and government sales declined amid U.S. uncertainty and China macro weakness. Currency translation added $0.37 billion to revenue.
The company continues to operate four major segments and highlights ongoing R&D investment, heavy use of acquisitions, and significant goodwill of $49.36 billion. It ended the year with about $39.38 billion of debt, 371,484,244 shares outstanding and roughly 125,000 employees. A new $5.0 billion repurchase authorization was approved, with $3.0 billion repurchased early in 2026.
Thermo Fisher Scientific Inc. issued four new series of senior unsecured notes totaling $4.8 billion to raise long-term debt capital. The company sold $1.0 billion of 4.215% Notes due 2031, $750 million of 4.550% Notes due 2033, $1.3 billion of 4.902% Notes due 2036 and $750 million of 5.546% Notes due 2046 in a public offering.
Thermo Fisher expects net proceeds of approximately $3.76 billion after underwriting discounts and expenses. It intends to use these funds primarily to pay a portion of the cash consideration for its previously announced acquisition of Clario Holdings, Inc., with any remainder available for general corporate purposes or temporary short-term investments.
The notes include standard optional redemption features before and after defined par call dates, a change-of-control repurchase right at 101% of principal upon specified rating downgrades, and customary covenants limiting secured debt on principal properties, sale-leaseback transactions, and certain mergers or asset sales.
Thermo Fisher Scientific executive vice president Gianluca Pettiti sold 400 shares of common stock in an open-market transaction at $541.20 per share. The sale on February 9, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.
After this transaction, Pettiti directly beneficially owned 20,752.223 shares of Thermo Fisher Scientific common stock. Rule 10b5-1 plans allow insiders to schedule trades in advance, helping separate personal trading decisions from later corporate developments.